ICU Medical (NASDAQ:ICUI) Issues Quarterly Earnings Results, Beats Estimates By $0.30 EPS

ICU Medical (NASDAQ:ICUI) released its earnings results on Thursday. The medical instruments supplier reported $2.44 EPS for the quarter, beating the consensus estimate of $2.14 by $0.30, FiscalAI reports. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%. The firm had revenue of $556.22 million during the quarter, compared to analyst estimates of $552.03 million. During the same period in the prior year, the firm posted $2.03 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year.

Here are the key takeaways from ICU Medical’s conference call:

• Q3 revenue was $556 million, up 5% organically, while adjusted EBITDA rose 8% to $114 million and adjusted EPS increased 20% to $2.44. Consumables and Infusion Systems each posted record sales.
• Management expects full-year adjusted EBITDA of $415 million–$435 million and adjusted EPS of $8.60–$9.00 to finish toward the high end of its existing ranges. Adjusted gross margin reached 42%, and the company reiterated its goal of reaching 43% by the end of 2027.
• Free cash flow was $83 million in Q3, supporting about $80 million of debt repayment and bringing net leverage to 2.0x. However, year-to-date cash flow benefited from tariff refunds and lower capital spending, and management expects Q4 free cash flow to be lower than Q3.
• Integration-related logistics problems disrupted international deliveries and weighed on Vital Care, which declined 10% organically in Q3; management expects a larger full-year decline for the segment. It said most of the operational issues should be resolved in Q4.
• ICU Medical reported progress on its product pipeline, including approvals for infusion pumps in Canada and Europe and plans to file a revised Medfusion 5000 syringe-pump application in the coming weeks. Several Consumables launches are planned for 2027, though the company said pump-install-base replacement is likely to unfold over 2027–2029.

ICU Medical Price Performance

Shares of ICU Medical stock opened at $172.11 on Friday. The business’s fifty day moving average price is $162.91 and its 200 day moving average price is $149.27. ICU Medical has a twelve month low of $113.37 and a twelve month high of $192.85. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $4.30 billion, a P/E ratio of 72.01, a PEG ratio of 2.04 and a beta of 0.88.

Analyst Upgrades and Downgrades

Several analysts have commented on ICUI shares. BTIG Research lifted their price target on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of ICU Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Raymond James Financial reissued a “strong-buy” rating and issued a $200.00 target price on shares of ICU Medical in a research report on Friday, August 7th. Zacks Research downgraded shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Needham & Company LLC boosted their target price on shares of ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $195.20.

ICU Medical News Roundup

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Q3 results exceeded expectations: ICU Medical reported earnings of $2.44 per share versus the $2.14 consensus estimate, while revenue of $556.22 million also topped forecasts. Revenue rose 4.4% year over year, and earnings increased from $2.03 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Full-year outlook remains solid: The company reaffirmed its 2026 guidance and expects results at the high end of its forecast range, supporting confidence in its near-term performance. Q3 results and guidance
• Positive Sentiment: Analyst targets moved higher: Piper Sandler raised its target to $200 and maintained an Overweight rating; KeyCorp lifted its target to $189 and also kept an Overweight rating. BTIG reiterated its Buy rating and $200 target. These endorsements signal continued analyst confidence in potential upside. BTIG rating update
• Neutral Sentiment: Management will present at the Jefferies Global Healthcare Conference in London on November 15–18. The appearance may provide an opportunity to discuss the business, but no new financial information was announced. Conference announcement

Insiders Place Their Bets

In related news, COO Christian Voigtlander sold 8,929 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.93, for a total transaction of $1,633,381.97. Following the completion of the sale, the chief operating officer owned 37,377 shares of the company’s stock, valued at approximately $6,837,374.61. This represents a 19.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elisha W. Finney sold 378 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the transaction, the director owned 4,871 shares in the company, valued at $888,860.08. The trade was a 7.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 21,830 shares of company stock worth $3,905,003. 2.10% of the stock is owned by insiders.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures and sells medical devices and systems used in infusion therapy, critical care and oncology. Its products are designed to support the delivery of fluids, medications and nutrition while helping healthcare providers improve safety and efficiency in clinical settings.

The company’s portfolio includes infusion pumps, dedicated and non-dedicated administration sets, needle-free connectors, intravenous solutions and other infusion consumables. ICU Medical also offers products for critical care monitoring and vascular access, as well as closed-system transfer devices and related technologies used in the preparation and administration of hazardous drugs.

Founded in 1984, ICU Medical has expanded through internal development and acquisitions, including the acquisition of Hospira’s infusion systems business in 2017 and Smiths Medical in 2022.